{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T10:17:59Z","timestamp":1772187479073,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.clml.2015.09.007","type":"journal-article","created":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T19:27:25Z","timestamp":1443727645000},"page":"778-784","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Prognostic Factors, Response to Treatment, and Survival in Patients With Chronic Myeloid Leukemia in Blast Phase: A Single-Institution Survey"],"prefix":"10.1016","volume":"15","author":[{"given":"Fernando","family":"P\u00e9rez-Jacobo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Tuna-Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Demichelis-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erick","family":"Crespo-Sol\u00eds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ubaldo","family":"Valencia-Rocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"Aguayo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"L\u00f3pez-Karpovitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2015.09.007_bib1","series-title":"World Health Organization Classification of Tumours Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"32","article-title":"Chronic myelogenous leukaemia, BCR-ABL1 positive","author":"Vardiman","year":"2008"},{"key":"10.1016\/j.clml.2015.09.007_bib2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/ajh.23691","article-title":"Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management","volume":"89","author":"Jabbour","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2015.09.007_bib3","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A\u00a0new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.clml.2015.09.007_bib4","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/0092-8674(92)90241-4","article-title":"Dominant negative MYC blocks transformation by ABL oncogenes","volume":"70","author":"Sawyers","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.clml.2015.09.007_bib5","first-page":"247","article-title":"Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia","volume":"13","author":"Shuai","year":"1996","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2015.09.007_bib6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/ng791","article-title":"BCR-ABL suppresses C\/EBPalpha expression through inhibitory action of hnRNP E2","volume":"30","author":"Perrotti","year":"2002","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2015.09.007_bib7","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.09.007_bib8","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer","volume":"7","author":"Melo","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2015.09.007_bib9","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.hoc.2004.03.011","article-title":"Natural history and staging of chronic myelogenous leukemia","volume":"18","author":"Cortes","year":"2004","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clml.2015.09.007_bib10","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia\u2014advances in biology and new approaches to treatment","volume":"349","author":"Goldman","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.09.007_bib11","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000046636","article-title":"Cytogenetic and molecular genetic evolution of chronic myeloid leukemia","volume":"107","author":"Johansson","year":"2002","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2015.09.007_bib12","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","article-title":"Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV","volume":"118","author":"Fabarius","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.09.007_bib13","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood-2012-03-380147","article-title":"How I treat CML blast crisis","volume":"120","author":"Hehlmann","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.09.007_bib14","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1200\/JCO.2005.05.531","volume":"23","author":"Soverini","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.09.007_bib15","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/leu.2010.298","article-title":"A\u00a0deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases","volume":"25","author":"Grossmann","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.09.007_bib16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11864-006-0012-y","article-title":"Blastic phase of chronic myelogenous leukemia","volume":"7","author":"Karbasian Esfahani","year":"2006","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.clml.2015.09.007_bib17","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/sj.leu.2401056","article-title":"Phase II study of carboplatin in blast crisis of chronic myeloid leukemia: Eastern Cooperative Oncology Group Study E1992","volume":"12","author":"Dutcher","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.09.007_bib18","first-page":"203","article-title":"Cladribine combined with mitoxantrone in the treatment of blastic phase of chronic myeloid leukemia","volume":"48","author":"Robak","year":"2001","journal-title":"Neoplasma"},{"key":"10.1016\/j.clml.2015.09.007_bib19","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s12032-009-9276-y","article-title":"A\u00a0pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia","volume":"27","author":"Dutcher","year":"2010","journal-title":"Med Oncol"},{"key":"10.1016\/j.clml.2015.09.007_bib20","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.1992.10.3.398","article-title":"Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor","volume":"10","author":"Kantarjian","year":"1992","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.09.007_bib21","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.09.007_bib22","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.09.007_bib23","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1182\/blood.V99.10.3547","article-title":"Imatinib mesylate (STI571) therapy for Philadelphia chromosome\u2013positive chronic myelogenous leukemia in blast phase","volume":"99","author":"Kantarjian","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.09.007_bib24","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.09.007_bib25","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3324\/haematol.13068","article-title":"Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up","volume":"93","author":"Palandri","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2015.09.007_bib26","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1002\/cncr.25123","article-title":"Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily","volume":"116","author":"Saglio","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2015.09.007_bib27","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/leu.2011.355","article-title":"Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase","volume":"26","author":"Giles","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.09.007_bib28","first-page":"513","volume":"91","author":"Gratwohl","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2015.09.007_bib29","first-page":"452","article-title":"The effect of prior exposure to imatinib on transplant-related mortality","volume":"91","author":"Deininger","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2015.09.007_bib30","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0002-9343(87)90754-6","article-title":"Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients","volume":"83","author":"Kantarjian","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2015.09.007_bib31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood.V55.1.29.29","article-title":"Combination chemotherapy for terminal-phase chronic granulocytic leukemia: Cancer and Leukemia Group B studies","volume":"55","author":"Coleman","year":"1980","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.09.007_bib32","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/0002-9343(77)90199-1","article-title":"Blast crisis of chronic granulocytic leukemia. Morphologic variants and therapeutic implications","volume":"63","author":"Rosenthal","year":"1977","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2015.09.007_bib33","first-page":"31","article-title":"Immunophenotypic characteristics of the blast crisis in chronic myeloid leukemia","volume":"49","author":"L\u00f3pez-Karpovitch","year":"1997","journal-title":"Rev Invest Clin"},{"key":"10.1016\/j.clml.2015.09.007_bib34","first-page":"685","article-title":"The morphological, immunophenotypical and cytogenetic characteristics study of blast crisis in chronic myeloid leukemia","volume":"41","author":"Tang","year":"2002","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"10.1016\/j.clml.2015.09.007_bib35","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1200\/JCO.1990.8.5.813","article-title":"Report of the National Cancer Institute\u2013sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia","volume":"8","author":"Cheson","year":"1990","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.09.007_bib36","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.09.007_bib37","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.hoc.2004.03.005","article-title":"Accelerated and blastic phases of chronic myelogenous leukemia","volume":"18","author":"Giles","year":"2004","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clml.2015.09.007_bib38","first-page":"494","article-title":"Survival, clinical and laboratory characteristics of de novo and secondary megakaryoblastic leukemia","volume":"55","author":"Crespo","year":"2003","journal-title":"Rev Invest Clin"},{"key":"10.1016\/j.clml.2015.09.007_bib39","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0145-2126(96)00054-9","article-title":"Extramedullary blast crisis in chronic myeloid leukemia","volume":"20","author":"Specchia","year":"1996","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2015.09.007_bib40","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/ajh.2830430104","article-title":"High incidence of meningeal leukemia in lymphoid blast crisis of chronic myelogenous leukemia","volume":"43","author":"Saikia","year":"1993","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2015.09.007_bib41","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2141.1990.tb07832.x","article-title":"A\u00a0study of prognostic factors in blast crisis of Philadelphia chromosome\u2013positive chronic myelogenous leukaemia","volume":"76","author":"Cervantes","year":"1990","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2015.09.007_bib42","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/1097-0142(19880815)62:4<672::AID-CNCR2820620404>3.0.CO;2-T","article-title":"Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside","volume":"62","author":"Kantarjian","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2015.09.007_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ajcp\/82.1.1","article-title":"Transformation of chronic myelogenous leukemia: clinical, morphologic, and cytogenetic features","volume":"82","author":"Muehleck","year":"1984","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clml.2015.09.007_bib44","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3324\/haematol.2009.006999","article-title":"Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials","volume":"94","author":"Silver","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2015.09.007_bib45","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1046\/j.1365-2141.1998.00542.x","article-title":"\u201cLymphoid\u201d blast crisis of chronic myeloid leukaemia is associated with distinct clinicohaematological features","volume":"100","author":"Cervantes","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2015.09.007_bib46","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.leukres.2010.11.004","article-title":"The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study)","volume":"35","author":"Deau","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2015.09.007_bib47","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/10428190601075973","article-title":"A\u00a0pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase","volume":"48","author":"Quintas-Cardama","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2015.09.007_bib48","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/cncr.28433","article-title":"HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia","volume":"120","author":"Strati","year":"2014","journal-title":"Cancer"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015012951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015012951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:26:41Z","timestamp":1761870401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265015012951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S2152265015012951"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2015.09.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Factors, Response to Treatment, and Survival in Patients With Chronic Myeloid Leukemia in Blast Phase: A Single-Institution Survey","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2015.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}